Having trouble accessing articles? Reset your cache.

Son of Dimebon

When Medivation Inc.'s Dimebon latrepirdine failed in a Phase III trial in Alzheimer's disease, it came as no surprise to skeptics of the compound who had long doubted the generic antihistamine, for which a mechanism of action could not be identified in AD. But now, in a quest for small molecule neurogenesis stimulators, researchers at The University of Texas Southwestern Medical Center at Dallas have identified a compound that has a structure and neuroprotective function surprisingly similar to those of Dimebon.1

The new molecule, P7C3, is more potent than Dimebon and could

Read the full 917 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE